QNR
TW EN

scroll

Go Top

普瑞默生物科技股份有限公司

Primo Biotechnology Co., Ltd

Highlights

Primo aims to promote a new model of precision medicine. We utilize the Taiwan-exclusive Multi Pronged Growth Engine to develop novel radioligand theranostics to integrate with other precision medical approaches and digital health. Ultimately, we would like to establish an interdisciplinary integrated model for the entire healthcare system. Primo’s business model is based on the technological foundations of clinical medicine with support by radiopharmaceutical development and production to pursue the research and development of novel radioligand theranostics. . In order to overcome existing medical and clinical issues, Primo further utilizes team-created, radiopharmaceutical-based pharmaco-imaging platforms to collaborate for the use of preclinical and clinical practices, and advance medical evolution for medical development and patient well being.

Services

  • 01

    Radiopharmaceutical development

  • 02

    Support of drug development

  • 03

    Non-clinical study

  • 04

    Support of research-orientated clinical trials

  • 05

    SCI paper and proposal writing

Back to list

Introduction

About Us History

Taiwan Spotlight

Health Overview Clinical Trial Focus International Accreditations
Clinical Trial Centers TCTC c-IRB
Resources News e-LEARNING Contact Us
All Contents Copyright 2019 Center for Drug Evaluation (CDE),Taiwan/ This website is operated by Center for Drug Evaluation (CDE), Taiwan